KOUNTOUPES DENHAM CARR & REID, LLC for TEVA PHARMACEUTICALS USA, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to comprehensive tax reform and the proposed border adjustment tax.
Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE HERSHEY CARR | — |
| LORI DENHAM | — |
| LISA KOUNTOUPES | — |
| DAVID PAUL PELUSO | — |
| MARY R "RANDI" REID | — |
| ROSE SULLIVAN (LISTED IN ERROR) | — |
Medicare/Medicaid MMM
House and Senate efforts to repeal and replace the Affordable Care Act including amendments to the H. R. 1628, including the Affordable Health Care Act of 2017, and versions of the Better Care Reconciliation Act.
Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE HERSHEY CARR | — |
| LISA KOUNTOUPES | — |
| DAVID PAUL PELUSO | — |
| ROSE SULLIVAN (LISTED IN ERROR) | — |
Pharmacy PHA
Proposals related to affordability and pricing of pharmaceuticals including H. R. 2212 and S.974 Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act; Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement and H.R. 2430, the FDA Reauthorization Act of 2017, and S.934, the FDA Reauthorization Act of 2017. Issues related to opioid abuse.
Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in this issues listed.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE HERSHEY CARR | — |
| LORI DENHAM | — |
| LISA KOUNTOUPES | — |
| DAVID PAUL PELUSO | — |
| ROSE SULLIVAN (LISTED IN ERROR) | — |
Health Issues HCR
House and Senate efforts to repeal and replace the Affordable Care Act including amendments to the H. R. 1628, the Affordable Health Care Ace of 2017, including versions of the Better Care Reconciliation Act as well as the Graham-Cassidy proposal. Proposals related to affordability and pricing of pharmaceuticals including draft Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; H. R. 2051 - FAST Generics Act; S.771- Improving Access to Affordable Drugs Act; S.469-Affordable and Safe Prescription Drug Importation Act: and H. R. 749-Lower Drugs Through Competition Act. Issues related to industry user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement and H.R. 2430, the FDA Reauthorization Act of 2017, and S.934, the FDA Reauthorization Act of 2017.
Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE HERSHEY CARR | — |
| LISA KOUNTOUPES | — |
| DAVID PAUL PELUSO | — |
| ROSE SULLIVAN (LISTED IN ERROR) | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.